Anti-Fibrinolytic Drugs - Sweden

Sweden

The Anti-Fibrinolytic Drugs market in Sweden is projected to reach a revenue of US$76.35m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 4.71%, resulting in a market volume of US$96.09m by 2029.
In global comparison, United States is expected to generate the highest revenue, reaching US$9,858.00m in 2024.
In Sweden, the demand for anti-fibrinolytic drugs is rising due to the increasing prevalence of bleeding disorders in the population.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Sweden has been experiencing steady growth in recent years.

Customer preferences: Swedish customers are increasingly concerned about their health and well-being, leading to a higher demand for pharmaceuticals. In particular, there has been a growing interest in anti-fibrinolytic drugs due to their effectiveness in treating bleeding disorders.

Trends in the market: One trend in the Anti-Fibrinolytic Drugs market in Sweden is the increased use of tranexamic acid, a commonly used anti-fibrinolytic drug. This is due to its effectiveness in treating a wide range of bleeding disorders, including menorrhagia, postpartum hemorrhage, and trauma-related bleeding. Another trend is the growing popularity of topical anti-fibrinolytic agents, which are used to control bleeding during surgery.

Local special circumstances: Sweden has a well-developed healthcare system that provides universal coverage to all citizens. This has led to a high demand for pharmaceuticals, including anti-fibrinolytic drugs. Additionally, Sweden has a high incidence of bleeding disorders, which has further increased the demand for these drugs.

Underlying macroeconomic factors: Sweden has a strong and stable economy, which has contributed to the growth of the Anti-Fibrinolytic Drugs market. Additionally, the Swedish government has implemented policies to promote the use of generic drugs, which has led to increased competition and lower prices for anti-fibrinolytic drugs. Finally, Sweden has a highly educated population that is well-informed about healthcare and pharmaceuticals, which has further increased the demand for these drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.